NO327267B1 - Fremgangsmate for amplifisering av malnukleinsyre - Google Patents
Fremgangsmate for amplifisering av malnukleinsyre Download PDFInfo
- Publication number
- NO327267B1 NO327267B1 NO20000538A NO20000538A NO327267B1 NO 327267 B1 NO327267 B1 NO 327267B1 NO 20000538 A NO20000538 A NO 20000538A NO 20000538 A NO20000538 A NO 20000538A NO 327267 B1 NO327267 B1 NO 327267B1
- Authority
- NO
- Norway
- Prior art keywords
- nucleic acid
- amplification
- carrier
- polymerase
- primer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000002253 acid Substances 0.000 title description 3
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 97
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 92
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 92
- 230000003321 amplification Effects 0.000 claims abstract description 77
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 77
- 238000006243 chemical reaction Methods 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 4
- 239000000539 dimer Substances 0.000 claims description 28
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- 230000000977 initiatory effect Effects 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- 244000309466 calf Species 0.000 claims description 6
- 210000001541 thymus gland Anatomy 0.000 claims description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 108010006785 Taq Polymerase Proteins 0.000 claims description 3
- 108060002716 Exonuclease Proteins 0.000 claims description 2
- 102000013165 exonuclease Human genes 0.000 claims description 2
- 239000013615 primer Substances 0.000 description 51
- 239000000047 product Substances 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 12
- 238000013459 approach Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000005382 thermal cycling Methods 0.000 description 4
- -1 without limitation Chemical class 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007849 hot-start PCR Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 108700034637 EC 3.2.-.- Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/015—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone
- A61L9/04—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone using substances evaporated in the air without heating
- A61L9/12—Apparatus, e.g. holders, therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
- A61L9/012—Deodorant compositions characterised by being in a special form, e.g. gels, emulsions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11849599P | 1999-02-03 | 1999-02-03 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20000538D0 NO20000538D0 (no) | 2000-02-02 |
| NO20000538L NO20000538L (no) | 2000-08-04 |
| NO327267B1 true NO327267B1 (no) | 2009-05-25 |
Family
ID=22378957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000538A NO327267B1 (no) | 1999-02-03 | 2000-02-02 | Fremgangsmate for amplifisering av malnukleinsyre |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6300075B1 (ja) |
| EP (1) | EP1026261B1 (ja) |
| JP (2) | JP2000279184A (ja) |
| KR (1) | KR100901392B1 (ja) |
| CN (1) | CN100379880C (ja) |
| AT (1) | ATE440147T1 (ja) |
| AU (1) | AU764914B2 (ja) |
| CA (1) | CA2295942C (ja) |
| DE (1) | DE60042767D1 (ja) |
| DK (1) | DK1026261T3 (ja) |
| ES (1) | ES2328443T3 (ja) |
| NO (1) | NO327267B1 (ja) |
| PT (1) | PT1026261E (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1422298B1 (en) * | 1999-07-09 | 2010-01-27 | Gen-Probe Incorporated | Detection of hiv-1 by nucleic acid amplification |
| AU2001290867A1 (en) | 2000-09-14 | 2002-03-26 | Caliper Technologies Corp. | Microfluidic devices and methods for performing temperature mediated reactions |
| US6949368B2 (en) * | 2001-01-30 | 2005-09-27 | The Trustees Of Princeton University | Compositions and methods for enhancing polynucleotide amplification reactions |
| EP1321532A1 (en) * | 2001-12-19 | 2003-06-25 | Boehringer Mannheim Gmbh | Reagent for improved PCR |
| US7772383B2 (en) * | 2002-01-25 | 2010-08-10 | The Trustees Of Princeton University | Chemical PCR: Compositions for enhancing polynucleotide amplification reactions |
| EP1532275A4 (en) * | 2002-07-26 | 2005-09-14 | Applera Corp | HOT START-UP BIOCHEMICAL REACTIONS BY MG |
| US20040235032A1 (en) * | 2003-05-19 | 2004-11-25 | Canon Kabushiki Kaisha | PCR amplification method, PCR primer set, PCR amplification product, and method for detection of nucleic acid using the amplification method |
| DE602005011754D1 (de) * | 2004-01-23 | 2009-01-29 | Bio Merieux Inc | Neuartiges nukleotidgemisch für ein verbessertes nukleinsäureamplifikationsverfahren |
| EP1605060A1 (en) * | 2004-06-10 | 2005-12-14 | Biodynamics S.R.L. | Methods and reaction mixture reagent for increasing the specificity and fidelity of polymerase reactions |
| US20070092899A1 (en) * | 2005-10-21 | 2007-04-26 | The Regents Of The University Of California | Multiple displacement amplification with blocker DNA |
| US8206924B2 (en) * | 2006-09-11 | 2012-06-26 | Osaka University | Trace mRNA amplification method and use thereof |
| GB0701253D0 (en) | 2007-01-23 | 2007-02-28 | Diagnostics For The Real World | Nucleic acid amplification and testing |
| WO2011046972A2 (en) * | 2009-10-12 | 2011-04-21 | Life Technologies Corporation | Compositions and methods for suppressing primer interactions |
| KR101162422B1 (ko) | 2009-11-30 | 2012-07-10 | 박수민 | 핵산 증폭용 조성물 |
| WO2013115067A1 (ja) * | 2012-01-31 | 2013-08-08 | タカラバイオ株式会社 | 核酸合成反応の向上方法 |
| UA117921C2 (uk) * | 2012-10-22 | 2018-10-25 | Байєр Кропсаєнс Нв | Композиція, пристрій та спосіб ампліфікації нуклеїнових кислот |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8918226D0 (en) * | 1989-08-09 | 1989-09-20 | Wellcome Found | Dna assays |
| US5646019A (en) * | 1989-10-24 | 1997-07-08 | Stratagene | Method for producing primed nucleic acid templates |
| US5567583A (en) * | 1991-12-16 | 1996-10-22 | Biotronics Corporation | Methods for reducing non-specific priming in DNA detection |
| US5338671A (en) | 1992-10-07 | 1994-08-16 | Eastman Kodak Company | DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody |
| US5491086A (en) | 1993-05-14 | 1996-02-13 | Hoffmann-La Roche Inc. | Purified thermostable nucleic acid polymerase and DNA coding sequences from pyrodictium species |
| CA2168712A1 (en) * | 1995-02-07 | 1996-08-08 | John William Henderson Sutherland | Use of exonuclease and/or glycosylase as supplements to anti-polymerase antibody to increase specificity in polymerase chain reaction |
| JPH09168400A (ja) * | 1995-12-20 | 1997-06-30 | Sekisui Chem Co Ltd | 核酸の定量方法 |
| JP3082908B2 (ja) * | 1996-07-12 | 2000-09-04 | 東洋紡績株式会社 | リボ核酸の単離方法 |
| AU2799400A (en) * | 1999-01-29 | 2000-08-18 | Bavarian Nordic Research Institute A/S | Multiplex real-time pcr |
-
2000
- 2000-01-28 US US09/493,351 patent/US6300075B1/en not_active Expired - Lifetime
- 2000-02-01 DK DK00300790T patent/DK1026261T3/da active
- 2000-02-01 CA CA002295942A patent/CA2295942C/en not_active Expired - Fee Related
- 2000-02-01 EP EP00300790A patent/EP1026261B1/en not_active Expired - Lifetime
- 2000-02-01 DE DE60042767T patent/DE60042767D1/de not_active Expired - Lifetime
- 2000-02-01 ES ES00300790T patent/ES2328443T3/es not_active Expired - Lifetime
- 2000-02-01 AT AT00300790T patent/ATE440147T1/de active
- 2000-02-01 PT PT00300790T patent/PT1026261E/pt unknown
- 2000-02-02 NO NO20000538A patent/NO327267B1/no not_active IP Right Cessation
- 2000-02-02 AU AU14877/00A patent/AU764914B2/en not_active Ceased
- 2000-02-03 CN CNB001046381A patent/CN100379880C/zh not_active Expired - Fee Related
- 2000-02-03 JP JP2000032660A patent/JP2000279184A/ja not_active Withdrawn
- 2000-02-03 KR KR1020000005497A patent/KR100901392B1/ko not_active IP Right Cessation
-
2011
- 2011-01-07 JP JP2011002508A patent/JP2011120594A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT1026261E (pt) | 2009-09-23 |
| NO20000538L (no) | 2000-08-04 |
| EP1026261A3 (en) | 2003-07-30 |
| AU764914B2 (en) | 2003-09-04 |
| US6300075B1 (en) | 2001-10-09 |
| JP2011120594A (ja) | 2011-06-23 |
| KR20000076606A (ko) | 2000-12-26 |
| EP1026261B1 (en) | 2009-08-19 |
| ATE440147T1 (de) | 2009-09-15 |
| CA2295942C (en) | 2009-01-27 |
| CN100379880C (zh) | 2008-04-09 |
| AU1487700A (en) | 2000-08-10 |
| EP1026261A2 (en) | 2000-08-09 |
| CN1271019A (zh) | 2000-10-25 |
| CA2295942A1 (en) | 2000-08-03 |
| DK1026261T3 (da) | 2009-11-02 |
| JP2000279184A (ja) | 2000-10-10 |
| DE60042767D1 (de) | 2009-10-01 |
| ES2328443T3 (es) | 2009-11-13 |
| NO20000538D0 (no) | 2000-02-02 |
| KR100901392B1 (ko) | 2009-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190002865A1 (en) | RNase H-Based Assays Utilizing Modified RNA Monomers | |
| US8911948B2 (en) | RNase H-based assays utilizing modified RNA monomers | |
| JP2011120594A (ja) | 核酸増幅法 | |
| US9434988B2 (en) | RNase H-based assays utilizing modified RNA monomers | |
| US10227641B2 (en) | RNase H-based assays utilizing modified RNA monomers | |
| AU2013381709A1 (en) | RNase H-based assays utilizing modified RNA monomers | |
| EP2828403A1 (en) | Modified rnase h enzymes and their uses | |
| US20170044507A1 (en) | Modified rnase h enzymes and their uses | |
| WO2018031625A2 (en) | Rnase h mutants in an emulsion | |
| AU2013203617A1 (en) | RNase-H-Based Assays Utilizing Modified RNA Monomers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |